Survival outcomes, metastases at diagnosis, and percent necrosis were evaluated in osteosarcoma patients (n = 86 and n = 43 for OS/metastases and percent necrosis, respectively) with various ANRIL expression levels. The gene discussed is CDKN2B-AS1; the disease is osteosarcoma.